Incentive-based Smoking Cessation for Methadone Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The prevalence of cigarette smoking among patients receiving opioid agonist treatment, such as methadone or buprenorphine maintenance, is more than three-fold that of the general population and is associated with increased morbidity and mortality. The overarching goal of this project is to systematically develop a voucher-based contingency-management (CM) intervention for promoting initial and longer-term abstinence from cigarette smoking in patients receiving methadone or buprenorphine treatment for their opioid abuse.
| Condition | Intervention | Phase |
|---|---|---|
|
Cigarette Smoking Among Patients Currently Receiving Methadone or Buprenorphine Treatment for Opioid Dependence |
Behavioral: incentive-based contingency management |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Incentive-based Smoking Cessation for Methadone Patients |
- percent of subjects abstinent during the second week of the two-week monitoring period [ Time Frame: continuously and at end of 2-week trial ] [ Designated as safety issue: No ]
- mean days of continuous abstinence achieved during the 2-week abstinence monitoring period and mean number days abstinent (non-continuous) [ Time Frame: continuously and at end of 2-week trial ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 170 |
| Study Start Date: | June 2007 |
| Estimated Study Completion Date: | June 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Contingent Voucher condition
Subjects in this condition will receive a brief education intervention plus voucher-based incentives contingent on demonstrating objective evidence of recent smoking abstinence.
|
Behavioral: incentive-based contingency management
Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).
|
|
Placebo Comparator: Noncontingent control condition
Subjects assigned to this control condition will receive the brief education and vouchers delivered independent of smoking status and yoked to the schedule of voucher earnings in the Contingent Voucher condition.
|
Behavioral: incentive-based contingency management
Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).
|
Detailed Description:
The prevalence of cigarette smoking among patients receiving opioid agonist treatment, such as methadone or buprenorphine maintenance, is more than three-fold that of the general population and is associated with increased morbidity and mortality. Despite these statistics, little is known about how to effectively help opioid-maintained patients to quit smoking. We believe a treatment that successfully promotes smoking cessation in these patients would offer exciting potential for dissemination. First, these treatment modalities are uniquely situated to offer an ideal setting for implementing smoking-cessation interventions. Many patients achieve significant periods of stability and drug abstinence and remain engaged in treatment for long periods of time, which can promote the frequent and prolonged clinical contact to enable success with smoking cessation. Second, opioid treatment programs often adhere to a uniform set of state and federal regulations, which could support the dissemination of an effective intervention throughout clinics across the country. Therefore, the overarching goal of this Behavior Therapy Development project is to systematically develop a voucher-based contingency-management (CM) intervention for promoting initial and longer-term abstinence from cigarette smoking in patients receiving methadone or buprenorphine treatment for their opioid abuse. Our first aim is to develop a CM treatment that will promote initial smoking abstinence in these patients using an intensive but brief 2-week intervention (Study 1). Our second aim will then be to integrate procedures for establishing initial abstinence with those designed for maintaining abstinence with the overarching goal of promoting smoking cessation that is sustained after the incentive program is discontinued (Study 2).
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- For inclusion in the proposed study, subjects must report smoking 10 or more cigarettes per day and have smoked at least that amount for the past year. Subjects must be maintained on a stable methadone or buprenorphine dose for the month before study intake, with no evidence of regular illicit-drug abuse (<30% positive specimens for illicit drugs in the past 30 days).
Exclusion Criteria:
- Participants will be excluded if they are currently pregnant and/or nursing or if they report regular THC use and are unwilling to stop before beginning the study (THC use will confound CO values when we aim to monitor smoking status).
Contacts and Locations| Contact: Stacey C. Sigmon, Ph.D. | 802-656-9987 | stacey.sigmon@uvm.edu |
| United States, Vermont | |
| Substance Abuse Treatment Center, University of Vermont | Recruiting |
| Burlington, Vermont, United States, 05401 | |
| Contact: Stacey C. Sigmon, Ph.D. 802-656-9987 stacey.sigmon@uvm.edu | |
| Principal Investigator: Stacey C. Sigmon, Ph.D. | |
| Principal Investigator: | Stacey C. Sigmon, Ph.D. | University of Vermont, Department of Psychiatry |
More Information
No publications provided
| Responsible Party: | Stacey C. Sigmon, Associate Professor, Fletcher Allen Health Care |
| ClinicalTrials.gov Identifier: | NCT00718835 History of Changes |
| Other Study ID Numbers: | R01-DA019550, R01DA019550 |
| Study First Received: | July 17, 2008 |
| Last Updated: | March 7, 2013 |
| Health Authority: | United States: Federal Government United States: Institutional Review Board |
Keywords provided by Fletcher Allen Health Care:
|
smoking cessation behavioral treatment contingency management |
opioid maintenance methadone buprenorphine |
Additional relevant MeSH terms:
|
Smoking Opioid-Related Disorders Habits Substance-Related Disorders Mental Disorders Methadone Analgesics, Opioid Analgesics Sensory System Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Central Nervous System Depressants Antitussive Agents Respiratory System Agents Narcotics |
ClinicalTrials.gov processed this record on May 22, 2013